Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
11 Septiembre 2023 - 6:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing targeted
radiotherapeutics with advanced platform technologies for central
nervous system cancers, today announced that the Company will
present data from its ReSPECT-LM clinical trial evaluating the
Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for
the treatment of leptomeningeal metastases at the Cancer Prevention
& Research Institute of Texas (CPRIT) Innovations in Cancer
Prevention and Research Conference VI. The conference is taking
place October 2-3, 2023, in Galveston, Tex. The poster presentation
is titled,
Report of Phase 1 Part A of the ReSPECT-LM
Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal
Metastases (LM).
The presentation will be showcased during the
Poster Session on October 3, beginning at 7:00 a.m. A copy of the
poster will be made available under the Presentations tab of the
Investors section of the Company’s website following the meeting at
https://ir.plustherapeutics.com.
In August 2023, Plus Therapeutics received an
advance payment of grant funds of approximately $1.9 million, as
planned, as part of its overall $17.6 million award contract, which
CPRIT executed in September 2022. The contract provides
for funding from CPRIT over the three-year grant period
starting on August 31, 2022, and follows the expected increase of
development costs as the ReSPECT-LM clinical trial progresses to
later stages.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage
pharmaceutical company developing targeted radiotherapeutics for
difficult-to-treat cancers of the central nervous system with the
potential to enhance clinical outcomes for patients. Combining
image-guided local beta radiation and targeted drug delivery
approaches, the Company is advancing a pipeline of product
candidates with lead programs in recurrent glioblastoma (GBM) and
leptomeningeal metastases (LM). The Company has built a robust
supply chain through strategic partnerships that enable the
development, manufacturing and future potential commercialization
of its products. Plus Therapeutics is led by an experienced and
dedicated leadership team and has operations in key cancer clinical
development hubs including Austin and San Antonio, Texas. For more
information, visit https://plustherapeutics.com/ and
https://respect-trials.com.
About the Cancer Prevention &
Research Institute of Texas (CPRIT)
CPRIT was created by the Texas Legislature and
approved by a statewide vote in 2007 to lead the Lone Star State’s
fight against cancer. In 2019, Texas voters again voted
overwhelmingly to continue CPRIT with an additional $3 billion for
a total $6 billion investment in cancer research and
prevention.
To date, CPRIT has awarded over $3 billion in
grants to Texas research institutions and organizations through its
academic research, prevention and product development research
programs. CPRIT has recruited 281 distinguished researchers,
supported the establishment, expansion or relocation of 52
companies to Texas and generated over $7.66 billion in additional
public and private investment. CPRIT funding has advanced
scientific and clinical knowledge and provided 8.2 million
life-saving cancer prevention and early detection services reaching
Texans from all 254 counties. Learn more at cprit.state.tx.us.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains statements that may
be deemed “forward-looking statements” within the meaning of U.S.
securities laws. All statements in this press release other than
statements of historical fact are forward-looking statements. These
forward-looking statements may be identified by future verbs, as
well as terms such as “designed to,” “will,” “can,” “potential,”
“focus,” “preparing,” “next steps,” “possibly,” and similar
expressions or the negatives thereof. Such statements are based
upon certain assumptions and assessments made by management in
light of their experience and their perception of historical
trends, current conditions, expected future developments and other
factors they believe to be appropriate. These statements include,
without limitation, statements regarding the following: the
potential promise of 186Re including the ability of 186Re to safely
and effectively deliver radiation directly to the tumor at high
doses; expectations as to the Company’s future performance
including the next steps in developing the Company’s current
assets; the Company’s clinical trials including statements
regarding the timing and characteristics of the ReSPECT-GBM and
ReSPECT-LM clinical trials; possible negative effects of 186Re; the
continued evaluation of 186Re including through evaluations in
additional patient cohorts; and the intended functions of the
Company’s platform and expected benefits from such functions.
The forward-looking statements included in this
press release are subject to a number of risks and uncertainties
that may cause actual results to differ materially from those
discussed in such forward-looking statements. These risks and
uncertainties include, but are not limited to: the Company’s actual
results may differ, including materially, from those anticipated in
these forward-looking statements as a result of various factors,
including, but not limited to, the following: the early stage of
the Company’s product candidates and therapies, the results of the
Company’s research and development activities, including
uncertainties relating to the clinical trials of its product
candidates and therapies; the Company’s liquidity and capital
resources and its ability to raise additional cash, the outcome of
the Company’s partnering/licensing efforts, risks associated with
laws or regulatory requirements applicable to it, market
conditions, product performance, litigation or potential
litigation, and competition within the cancer diagnostics and
therapeutics field, among others; and additional risks described
under the heading “Risk Factors” in the Company’s Securities and
Exchange Commission filings, including in the Company’s annual and
quarterly reports. There may be events in the future that the
Company is unable to predict, or over which it has no control, and
its business, financial condition, results of operations and
prospects may change in the future. The Company assumes no
responsibility to update or revise any forward-looking statements
to reflect events, trends or circumstances after the date they are
made unless the Company has an obligation under U.S. federal
securities laws to do so.
Investor ContactPeter VozzoICR Westwicke(443)
213-0505Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerICR Westwicke(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Plus Therapeutics (NASDAQ:PSTV)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024